Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Compass Therapeutics Inc.

CMPX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.25

▼ -0.44%

Market Cap $405.20M · Vol 376.19K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$405.20M

Small Cap

Div Yield

N/A

EPS Growth

-17.95%

YoY

RSI (14)

58.33

Momentum

Beta

0.95

vs Market

52W High

$6.85

67.15% below

52W Low

$1.62

39.32% above

Volume

376.19K

Avg 801.76K

P/B

4.87

Price-to-book

ROE

N/A

Return on equity

Free Float

79.09%

Public shares

Shariah Compliance8 STANDARDS

✗ Compass Therapeutics Inc. (CMPX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CMPX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.65%

+2.74%

+13.64%

-64.17%

YTD

-58.10%

-23.73%

-8.91%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-66,489,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-36.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.87
P/FCF	N/A
EPS Growth	-17.95%
Outstanding Shares	180.09M

Technical Indicators

50-Day SMA	$2.10
200-Day SMA	$4.11
RSI (14)	58.33
Beta	0.95
52-Week High	$6.85
52-Week Low	$1.62

Volume Today	376.19K
Avg Daily Volume (30D)	801.76K
Relative Volume	0.47x
Volatility (10D)	70.07
Volatility (30D)	53.27
Free Float	79.09%

Analyst Consensus

BUY

Current Price $2.25

Mean Target $8.92

52W Low$1.62 52W High$6.85

Current

Target

$1.62 $6.85

Current Analyst target

+296.30% upside potential · 15 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00LPXKF34

ISINUS20454B1044

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.